217 related articles for article (PubMed ID: 24785509)
81. DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.
Carignan D; Lessard T; Villeneuve L; Desjardins S; Magnan S; Després P; Martin AG; Foster W; Guillemette C; Lévesque É; Vigneault E
Prostate; 2020 May; 80(8):632-639. PubMed ID: 32201973
[TBL] [Abstract][Full Text] [Related]
82. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes.
Giotopoulos G; Symonds RP; Foweraker K; Griffin M; Peat I; Osman A; Plumb M
Br J Cancer; 2007 Mar; 96(6):1001-7. PubMed ID: 17325707
[TBL] [Abstract][Full Text] [Related]
83. Identification of a breast cancer susceptibility locus at 4q31.22 using a genome-wide association study paradigm.
Sapkota Y; Yasui Y; Lai R; Sridharan M; Robson PJ; Cass CE; Mackey JR; Damaraju S
PLoS One; 2013; 8(5):e62550. PubMed ID: 23717390
[TBL] [Abstract][Full Text] [Related]
84. Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.
Batra J; Lose F; O'Mara T; Marquart L; Stephens C; Alexander K; Srinivasan S; Eeles RA; Easton DF; Al Olama AA; Kote-Jarai Z; Guy M; Muir K; Lophatananon A; Rahman AA; Neal DE; Hamdy FC; Donovan JL; Chambers S; Gardiner RA; Aitken J; Yaxley J; Kedda MA; Clements JA; Spurdle AB
PLoS One; 2011; 6(11):e26527. PubMed ID: 22132073
[TBL] [Abstract][Full Text] [Related]
85. Shared genetic factors for age at natural menopause in Iranian and European women.
Rahmani M; Earp MA; Ramezani Tehrani F; Ataee M; Wu J; Treml M; Nudischer R; P-Behnami S; ; Perry JR; Murabito JM; Azizi F; Brooks-Wilson A
Hum Reprod; 2013 Jul; 28(7):1987-94. PubMed ID: 23592221
[TBL] [Abstract][Full Text] [Related]
86. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study.
Teraoka SN; Bernstein JL; Reiner AS; Haile RW; Bernstein L; Lynch CF; Malone KE; Stovall M; Capanu M; Liang X; Smith SA; Mychaleckyj J; Hou X; Mellemkjaer L; Boice JD; Siniard A; Duggan D; Thomas DC; ; Concannon P
Breast Cancer Res; 2011; 13(6):R114. PubMed ID: 22087758
[TBL] [Abstract][Full Text] [Related]
87. Modifiable risk factors for acute skin toxicity in adjuvant breast radiotherapy: Dosimetric analysis and review of the literature.
Keenan LG; Lavan N; Dunne M; McArdle O
Med Dosim; 2019 Spring; 44(1):51-55. PubMed ID: 29576443
[TBL] [Abstract][Full Text] [Related]
88. SNP eQTL status and eQTL density in the adjacent region of the SNP are associated with its statistical significance in GWA studies.
Gorlov I; Xiao X; Mayes M; Gorlova O; Amos C
BMC Genet; 2019 Nov; 20(1):85. PubMed ID: 31718536
[TBL] [Abstract][Full Text] [Related]
89. Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses.
Lu Y; Sun J; Kader AK; Kim ST; Kim JW; Liu W; Sun J; Lu D; Feng J; Zhu Y; Jin T; Zhang Z; Dimitrov L; Lowey J; Campbell K; Suh E; Duggan D; Carpten J; Trent JM; Gronberg H; Zheng SL; Isaacs WB; Xu J
Prostate; 2012 Mar; 72(4):376-85. PubMed ID: 21671247
[TBL] [Abstract][Full Text] [Related]
90. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
91. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation.
Sini C; Fiorino C; Perna L; Noris Chiorda B; Deantoni CL; Bianchi M; Sacco V; Briganti A; Montorsi F; Calandrino R; Di Muzio N; Cozzarini C
Radiother Oncol; 2016 Jan; 118(1):79-84. PubMed ID: 26702990
[TBL] [Abstract][Full Text] [Related]
92. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
93. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
94. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer.
Kerns SL; Amidon Morlang A; Lee SM; Peterson DR; Marples B; Zhang H; Bylund K; Rosenzweig D; Hall W; De Ruyck K; Rosenstein BS; Stock RG; Gómez-Caamaño A; Vega A; Sosa-Fajardo P; Taboada-Valladares B; Aguado-Barrera ME; Parker C; Veldeman L; Fonteyne V; Bultijnck R; Talbot CJ; Symonds RP; Johnson K; Rattay T; Webb A; Lambrecht M; de Ruysscher D; Vanneste B; Choudhury A; Elliott RM; Sperk E; Herskind C; Veldwijk MR; Rancati T; Avuzzi B; Valdagni R; Azria D; Farcy Jacquet MP; Chang-Claude J; Seibold P; West C; Janelsins M; Chen Y; Messing E; Morrow G;
Radiother Oncol; 2022 Mar; 168():75-82. PubMed ID: 35077710
[TBL] [Abstract][Full Text] [Related]
95. Predicting the germline dependence of hematuria risk in prostate cancer radiotherapy patients.
Oh JH; Lee S; Thor M; Rosenstein BS; Tannenbaum A; Kerns S; Deasy JO
Radiother Oncol; 2023 Aug; 185():109723. PubMed ID: 37244355
[TBL] [Abstract][Full Text] [Related]
96. Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions.
Qian DC; Byun J; Han Y; Greene CS; Field JK; Hung RJ; Brhane Y; Mclaughlin JR; Fehringer G; Landi MT; Rosenberger A; Bickeböller H; Malhotra J; Risch A; Heinrich J; Hunter DJ; Henderson BE; Haiman CA; Schumacher FR; Eeles RA; Easton DF; Seminara D; Amos CI
Hum Mol Genet; 2015 Dec; 24(25):7406-20. PubMed ID: 26483192
[TBL] [Abstract][Full Text] [Related]
97. Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer.
Naderi E; Schack LMH; Welsh C; Sim AYL; Aguado-Barrera ME; Dudding T; Summersgil H; Martínez-Calvo L; Ong EHW; Odding Y; Varela-Pazos A; Steenbakkers RJHM; Crijns APG; Jena R; Pring M; Dennis J; Lobato-Busto R; Alsner J; Ness A; Nutting C; Thomson DJ; Gómez-Caamaño A; Eriksen JG; Thomas SJ; Bates AM; Overgaard J; Cascallar-Caneda LM; Duprez F; Barnett GC; Dorling L; Chua MLK; Vega A; West CML; Langendijk JA; Nicolaj Andreassen C; Alizadeh BZ;
Radiother Oncol; 2022 Nov; 176():138-148. PubMed ID: 36191651
[TBL] [Abstract][Full Text] [Related]
98. Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?
Herskind C; Talbot CJ; Kerns SL; Veldwijk MR; Rosenstein BS; West CM
Cancer Lett; 2016 Nov; 382(1):95-109. PubMed ID: 26944314
[TBL] [Abstract][Full Text] [Related]
99. Radiogenomics: the search for genetic predictors of radiotherapy response.
Kerns SL; West CM; Andreassen CN; Barnett GC; Bentzen SM; Burnet NG; Dekker A; De Ruysscher D; Dunning A; Parliament M; Talbot C; Vega A; Rosenstein BS
Future Oncol; 2014 Dec; 10(15):2391-406. PubMed ID: 25525847
[TBL] [Abstract][Full Text] [Related]
100. A Review of Prostate Cancer Genome-Wide Association Studies (GWAS).
Benafif S; Kote-Jarai Z; Eeles RA;
Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):845-857. PubMed ID: 29348298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
